[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 509
Citations 0
In This Issue of JAMA Dermatology
August 2017


JAMA Dermatol. 2017;153(8):735. doi:10.1001/jamadermatol.2016.1700

Rising US pharmaceutical costs are a source of increasing financial burden for payers and patients. Increased pharmaceutical costs are often attributed to novel agents that require funding for development and testing. In this retrospective cost analysis of Medicare Part D participants who filled prescriptions for topical steroids, Song et al demonstrate that most topical steroids prescribed were generic drugs. The sharp increase in Medicare and out-of-pocket spending on topical steroids has been driven by higher costs for generics. Clinical decision support tools to enable lower-cost generic topical steroid substitutions from the corresponding potency class may reduce drug expenditures.